Form 4: Coya Therapeutics Director Acquires Stock Options

Dov A. Goldstein, a director at Coya Therapeutics, acquired 5,000 stock options on January 1, 2025.

Summary

• Dov A. Goldstein, a director of Coya Therapeutics, Inc., was granted 5,000 stock options on January 1, 2025.
• The options have an exercise price of $5.73 per share.
• The options vest 100% on the first anniversary of the grant date, which is January 1, 2026.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction, indicating confidence from a director, which is generally positive. However, it's not a major event that would drastically alter sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard transaction for a director of a publicly traded company, often used as part of compensation packages to align the interests of management with shareholders.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedule of one year is fairly standard, aligning with typical incentive structures.
• The exercise price of $5.73 would be compared to the current market price of the stock to determine the value of the options.

Stakeholder Impact

• The stock option grant could positively impact shareholder sentiment by demonstrating director confidence in the company.

Key Dates

Keywords

stock options, director, Coya Therapeutics, insider trading, equity, vesting